CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC
CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC
FGFR as a tumour agnostic indicator and its importance in the diagnosis and treatment of multiple solid tumour types
ASCO 2021: Precision and molecular reporting for prostate cancer
COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia